ABOUT ANSHI
Developing innovative small molecule drugs to revolutionize the treatment of chronic diseases in China.
At Anshi Pharmaceutical, our mission is to lead the way in developing cutting-edge compounds to address some of the most pressing healthcare challenges of our time—non-alcoholic steatohepatitis (NASH), obesity, and osteoporosis. We recognize that these conditions affect millions of lives worldwide, and we are driven by a steadfast commitment to bring transformative solutions to patients in need.
We envision a future where NASH, obesity, and osteoporosis are no longer insurmountable health concerns. Instead, they are met with innovative treatments that offer renewed hope, improved well-being, and a better quality of life for patients. Our unwavering dedication to scientific excellence and patient-centric values fuels our quest to redefine healthcare standards and make a tangible impact on global health.
With more than 1,200 employees with diverse technical, business, language and geographical backgrounds and a strong track record of successfully commercializing major drugs in the US & China market, our team understands the regulatory and marketing requirements for success.
We foster an environment that inspires colleagues to expand their horizons and strive to achieve what was thought to be impossible. Led by our Chief Executive Office, Ryan Chen, our teams of seasoned professionals apply their extensive experience to enable the development of new medicines. We work across traditional disciplines to answer difficult scientific, regulatory, and business questions.
A&Z and Anshi incorporated in the US and China to supply global markets
China manufacturing facility successfully inspected by the US FDA
Biopharmaceutical incorporated
Research & Development Center of Excellence established
Product portfolio expanded by the launch of several major products in China, including ursodeoxycholic acid, the first generic approval in China; Strategic investment in Rabome Inc., FIC drug for osteonecrosis
Synthetic bear bile acid phase Il clinical trials completed
Anshi brings world-class experience at multinational pharmaceutical companies that ensures success for the company’s visionary approach to drug development and commercialization. With a strong track record of successfully introducing major drugs into US and China markets, our team understands the regulatory and market requirements.
Chief Executive Officer
Chief Regulatory & Clinical Officer
Chief Science Officer
Chief Business Officer